IFNA1 and Cirrhosis: Last, based on the sub-group analyses of patients with compensated cirrhosis in several large clinical trials28, 29, 30, the up-to-date guidance for the treatment of HCV infection of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America does not recommend mono or dual therapy with IFN for the treatment patients with HCV-related cirrhosis, and has recommended the use of highly potent DAA oral combination regimens for HCV infected patients.